These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 23451999)
1. Cancer as the main aging factor for humans: the fundamental role of 5-methoxy-tryptamine in reversal of cancer-induced aging processes in metabolic and immune reactions by non-melatonin pineal hormones. Lissoni P; Messina G; Rovelli F Curr Aging Sci; 2012 Dec; 5(3):231-5. PubMed ID: 23451999 [TBL] [Abstract][Full Text] [Related]
2. Total pineal endocrine substitution therapy (TPEST) as a new neuroendocrine palliative treatment of untreatable metastatic solid tumor patients: a phase II study. Lissoni P; Malugani F; Brivio F; Piazza A; Vintimilla C; Giani L; Tancini G Neuro Endocrinol Lett; 2003; 24(3-4):259-62. PubMed ID: 14523367 [TBL] [Abstract][Full Text] [Related]
3. Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms. Lissoni P Ann N Y Acad Sci; 2000; 917():560-7. PubMed ID: 11268384 [TBL] [Abstract][Full Text] [Related]
4. Oncostatic activity of pineal neuroendocrine treatment with the pineal indoles melatonin and 5-methoxytryptamine in untreatable metastatic cancer patients progressing on melatonin alone. Lissoni P; Rovelli F; Frassineti A; Fumagalli L; Malysheva O; Conti A; Maestroni G Neuro Endocrinol Lett; 2000; 21(4):319-323. PubMed ID: 11455367 [TBL] [Abstract][Full Text] [Related]
5. Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin. Lissoni P; Fumagalli L; Paolorossi F; Rovelli F; Roselli MG; Maestroni GJ J Biol Regul Homeost Agents; 1997; 11(3):119-22. PubMed ID: 9498162 [TBL] [Abstract][Full Text] [Related]
6. Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agent. Lissoni P Pathol Biol (Paris); 2007; 55(3-4):198-200. PubMed ID: 17451889 [TBL] [Abstract][Full Text] [Related]
7. Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone. Lissoni P; Cazzaniga M; Tancini G; Scardino E; Musci R; Barni S; Maffezzini M; Meroni T; Rocco F; Conti A; Maestroni G Eur Urol; 1997; 31(2):178-81. PubMed ID: 9076462 [TBL] [Abstract][Full Text] [Related]
8. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations. Cerea G; Vaghi M; Ardizzoia A; Villa S; Bucovec R; Mengo S; Gardani G; Tancini G; Lissoni P Anticancer Res; 2003; 23(2C):1951-4. PubMed ID: 12820485 [TBL] [Abstract][Full Text] [Related]
9. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Lissoni P; Barni S; Tancini G; Ardizzoia A; Ricci G; Aldeghi R; Brivio F; Tisi E; Rovelli F; Rescaldani R Br J Cancer; 1994 Jan; 69(1):196-9. PubMed ID: 8286206 [TBL] [Abstract][Full Text] [Related]
10. Is there a role for melatonin in supportive care? Lissoni P Support Care Cancer; 2002 Mar; 10(2):110-6. PubMed ID: 11862501 [TBL] [Abstract][Full Text] [Related]
11. Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms. Lissoni P; Giani L; Zerbini S; Trabattoni P; Rovelli F Nat Immun; 1998; 16(1):27-33. PubMed ID: 9789122 [TBL] [Abstract][Full Text] [Related]
12. Reduction of cisplatin-induced anemia by the pineal indole 5-methoxytryptamine in metastatic lung cancer patients. Lissoni P; Malugani F; Bukovec R; Bordin V; Perego M; Mengo S; Ardizzoia A; Tancini G Neuro Endocrinol Lett; 2003; 24(1-2):83-5. PubMed ID: 12743539 [TBL] [Abstract][Full Text] [Related]
13. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Lissoni P Pathol Biol (Paris); 2007; 55(3-4):201-4. PubMed ID: 17446010 [TBL] [Abstract][Full Text] [Related]
14. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system. Lissoni P; Malugani F; Malysheva O; Kozlov V; Laudon M; Conti A; Maestroni G Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238 [TBL] [Abstract][Full Text] [Related]
15. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies. Lissoni P; Bolis S; Brivio F; Fumagalli L Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160 [TBL] [Abstract][Full Text] [Related]